EZRA

EZRA is a $65M micro-cap whose actual business is going the wrong way. FY2025 revenue fell 11.6% to $12.4M — and the MD&A reveals why: management sold off cash-generating brokerage assets (Fortman, EBS, USBA) to pay down debt, so the shrinkage is structural, not cyclical. The company has lost money in four of the last five years (only FY2022 was positive), booked a -$9.01M operating loss (margin -72.5%), burned $3.09M in operating cash, and carries a -$55.1M accumulated deficit against just $6.43M of equity (ROE -108.7%). This is not a fixable earnings dip; it's a business without a demonstrated path to profitability at its current scale.

The capital structure is the disqualifier. Shares outstanding exploded 640.6% YoY to 21.3M, funded by an ATM program (~$2.2M raised), a $10M White Lion equity line, and a January 2026 public offering — a dilution machine running because the company cannot self-fund. The only cash figure provided is a stale FY2020 tag of $530K, so current liquidity is effectively unknown, yet the strategy (milestone tranches to take Enquantum from 8% to 51%) explicitly 'will require additional capital deployment.' More dilution is not a risk; it is the stated plan. Compounding this, a December 2025 Nasdaq notice flags the stock below the $1.00 minimum bid — a live delisting clock.